Cite
HARVARD Citation
Ziemssen, F. et al. (n.d.). Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. Expert opinion on drug safety. 15 (1), pp. 75-87. [Online].